{
    "paper_id": "041da5653da28039cdc4aae02ac994c9e321ee32",
    "metadata": {
        "title": "Journal Pre-proof Potential role of Janus kinase inhibitors in COVID-19",
        "authors": [
            {
                "first": "Maddalena",
                "middle": [],
                "last": "Napolitano",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Gabriella",
                "middle": [],
                "last": "Fabbrocini",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Cataldo",
                "middle": [],
                "last": "Patruno",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Authors: Maddalena Napolitano 1 , Gabriella Fabbrocini 2 , Cataldo Patruno 3 Affiliation: 1 Recently, Richardson et 2 al proposed baricitinib as potential treatment for pneumonia during COVID-19, because it would be capable to reduce the ability of the virus to infect lung cells. 2 The lung is particularly prone to SARS-CoV-2 infection probably for the presence of AT2 cell. This cell expresses on its surface the protein ACE2, a receptor used by the virus to invade the host. 2 One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). 2 Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles. 3 Baricitinib on therapeutic dosing is reported to be able to inhibit AAK1 functions and to bind the cyclin G-associated kinase, another regulator of endocytosis of virus. 3 In both phase II and phase III trials on atopic dermatitis (AD) baricitinib had a good safety profile: headache, nasopharyngitis, and increase in CPK levels were the most common adverse events. 4 The increased Incidence of infective diseases such as reactivation of Varicella Zoster, Herpes Simplex and Epstein Barr Virus strains reported in trials for rheumatoid arthritis, was not observed in AD patients. 4 Upadacitinib is a selective JAK1 inhibitor and is currently being investigated for AD treatment. 4",
            "cite_spans": [
                {
                    "start": 90,
                    "end": 91,
                    "text": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 281,
                    "end": 282,
                    "text": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 479,
                    "end": 480,
                    "text": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 571,
                    "end": 572,
                    "text": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 710,
                    "end": 711,
                    "text": "3",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 882,
                    "end": 883,
                    "text": "3",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1078,
                    "end": 1079,
                    "text": "4",
                    "ref_id": null
                },
                {
                    "start": 1292,
                    "end": 1293,
                    "text": "4",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Title: Potential role of Janus kinase inhibitors in COVID-19"
        },
        {
            "text": "Preclinical research showed that disruption of JAK1 signaling induced by upatacitinib reduced the expression of T-helper(Th)-2 and Th22 cytokines, but also the levels of interleukin (IL)-6, through inhibition phosphorylation of STAT3. 5 It is also known that IL-6, plays a central role in the \"cytokine storm\" damaging lung in Covid-19 patients. 1 Recently, tocilizumab a monoclonal antibody that competitively inhibits the binding of IL-6 to its receptor has been used to treat complications of COVID-19 induced pneumonia and China's National Health Commission and the Italian Medicines Agency approved the tocilizumab use in severe patients with extensive lung disease and with elevated IL-6 levels detected by the laboratory.",
            "cite_spans": [
                {
                    "start": 235,
                    "end": 236,
                    "text": "5",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 346,
                    "end": 347,
                    "text": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "Title: Potential role of Janus kinase inhibitors in COVID-19"
        },
        {
            "text": "All these preclinical data seem to suggest that treatment with both baricitinib and upatacitinib should not be stopped during COVID-19 pandemic. Obviously, a careful assessment is mandatory for each individual patient reporting any side effect.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Title: Potential role of Janus kinase inhibitors in COVID-19"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "The use of Janus kinase inhibitors in the time of SARS-CoV-2",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Peterson",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Damsky",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "King",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Am Acad Dermatol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Richardson",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Griffin",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tucker",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Oechsle",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Phelan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stebbing",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "30--31",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "Y"
                    ],
                    "last": "Pu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Schor",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Antiviral Res",
            "volume": "155",
            "issn": "",
            "pages": "67--75",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Napolitano",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fabbrocini",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Cinelli",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Stingeni",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Patruno",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Asthma Allergy",
            "volume": "13",
            "issn": "",
            "pages": "89--94",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Guttman-Yassky",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Tha\u00e7i",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Pangan",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "C"
                    ],
                    "last": "Hong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Papp",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Reich",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Beck",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Mohamed",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Othman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Anderson",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "D"
                    ],
                    "last": "Teixeira",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "I"
                    ],
                    "last": "Silverberg",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Allergy Clin Immunol",
            "volume": "145",
            "issn": "3",
            "pages": "877--884",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Parmentier",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Voss",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Graff",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Schwartz",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Argiriadi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Friedman",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "S"
                    ],
                    "last": "Camp",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Padley",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "George",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hyland",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rosebraugh",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wishart",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Olson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Long",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "BMC Rheumatol",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Key words: COVID-19, atopic dermatitis, JAK inhibitors, upadacitinib, baricitinib, infection Conflict of interest: M.N. acted as speaker for Sanofi G.F. acted as speaker and consultant for AbbVie and Leo Pharma C.P. acted as speaker and consultant for AbbVie, Novartis, Pfizer and Sanofi Dear Editor, We read with interest the letter of Peterson D et al, about The use of Janus kinase inhibitors (JAKinh) in the time of SARS-CoV-2. 1 The authors reported that discontinuation of JAKinh in the setting of initial infection, such as with SARS-CoV-2, may be beneficial given the role of JAK-STAT dependent Type I (alpha/beta) and Type II (gamma) interferons in 66 anti-viral immunity. However, literature data regarding possible use of JAKinh in COVID 19 patients is growing.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy; 2 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 3 Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}